S
Shulin Li
Researcher at University of Texas MD Anderson Cancer Center
Publications - 130
Citations - 6508
Shulin Li is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Interleukin 12. The author has an hindex of 36, co-authored 127 publications receiving 5009 citations. Previous affiliations of Shulin Li include University of Texas at Austin & Louisiana State University.
Papers
More filters
Journal ArticleDOI
Vimentin in cancer and its potential as a molecular target for cancer therapy.
Arun Satelli,Shulin Li +1 more
TL;DR: By virtue of its overexpression in cancer and its association with tumor growth and metastasis, vimentin serves as an attractive potential target for cancer therapy; however, more research would be crucial to evaluate its specific role in cancer.
Journal ArticleDOI
EMT, CTCs and CSCs in tumor relapse and drug-resistance
TL;DR: The association of the EMT program with CTCs and CSCs is extensively discussed to characterize a subpopulation of patients prone to relapses and to facilitate the development of new or enhanced personalized therapeutic regimens.
Journal ArticleDOI
The role of the liver in sepsis.
TL;DR: The central role of liver in the host immune response to sepsis and in clinical outcomes is summarized andAttenuating liver injury and restoring liver function lowers morbidity and mortality rates in patients with sepsi.
Journal ArticleDOI
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
Tiffany R. Hodges,Martina Ott,Joanne Xiu,Zoran Gatalica,Jeff Swensen,Shouhao Zhou,Jason T. Huse,John de Groot,Shulin Li,Willem W. Overwijk,David Spetzler,Amy B. Heimberger +11 more
TL;DR: On the basis of a variety of potential biomarkers of response to immune checkpoints, only small subsets of glioma patients are likely to benefit from monotherapy immune checkpoint inhibition.
Journal ArticleDOI
Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles
Ronnie H. Fang,Che Ming Jack Hu,Kevin Chen,Brian T. Luk,Cody W. Carpenter,Weiwei Gao,Shulin Li,Dong Er Zhang,Weiyue Lu,Liangfang Zhang +9 more
TL;DR: RBC membrane-cloaked polymeric nanoparticles represent an emerging nanocarrier platform with extended circulation in vivo with receptor-specific targeting against model cancer cell lines through lipid-insertion method.